Open-label, dose escalation, first-in-human study of HLX20, an anti PD-L1 monoclonal antibody, in patients with metastatic or recurrent solid tumors who have failed standard therapy
Phase 1
Not yet recruiting
- Conditions
- Metastatic Solid Tumour for patients who have failed/not tolerated/not available standard treatment
- Registration Number
- ACTRN12618000977279
- Lead Sponsor
- Shanghai Henlius Biotech, Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not yet recruiting
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What is the molecular mechanism of HLX20 in targeting PD-L1 for advanced solid tumors?
How does HLX20 compare to other PD-L1 inhibitors in treating metastatic cancers post-standard therapy?
Which biomarkers are associated with response to HLX20 in patients with PD-L1 expressing tumors?
What are the potential adverse events and management strategies for HLX20 in oncology?
Are there combination therapies involving HLX20 and other immunotherapics for solid tumors?